[Un nouveau modèle mathématique pour lʼoptimisation des combinaisons antiangiogéniques/cytotoxiques en cancérologie]
Nous proposons ici un nouveau modèle mathématique dédié à lʼoptimisation thérapeutique des combinaisons antiangiogéniques/cytotoxiques en cancérologie. Ce modèle permet de rendre compte des interactions non linéaires entre les deux traitements et notamment de lʼinfluence de lʼétat de la vasculature sur lʼaccès à la tumeur des molécules administrées. A terme, ce modèle pourra être utilisé en oncologie clinique pour piloter les protocoles chimiothérapeutiques reposant sur la combinaison dʼun antiangiogénique et de médicaments cytotoxiques, afin dʼen améliorer lʼefficacité antitumorale.
We present in this Note a new mathematical model designed to optimize and to rationalize the association between cytotoxic and antiangiogenic drugs in the treatment of a primary tumor. This model takes into account the non-linear interlinkings between both drugs. In particular, this original model integrates the influence of the vasculature state on the delivery of the drugs to the tumor. In the future, this model could be used in clinical oncology to optimize antiangiogenic-based combinational regimen so as to ensure a maximum efficacy.
Accepté le :
Publié le :
@article{CRMATH_2012__350_1-2_23_0,
author = {Benzekry, S\'ebastien and Chapuisat, Guillemette and Ciccolini, Joseph and Erlinger, Alice and Hubert, Florence},
title = {A new mathematical model for optimizing the combination between antiangiogenic and cytotoxic drugs in oncology},
journal = {Comptes Rendus. Math\'ematique},
pages = {23--28},
publisher = {Elsevier},
volume = {350},
number = {1-2},
year = {2012},
doi = {10.1016/j.crma.2011.11.019},
language = {en},
url = {http://www.numdam.org/articles/10.1016/j.crma.2011.11.019/}
}
TY - JOUR AU - Benzekry, Sébastien AU - Chapuisat, Guillemette AU - Ciccolini, Joseph AU - Erlinger, Alice AU - Hubert, Florence TI - A new mathematical model for optimizing the combination between antiangiogenic and cytotoxic drugs in oncology JO - Comptes Rendus. Mathématique PY - 2012 SP - 23 EP - 28 VL - 350 IS - 1-2 PB - Elsevier UR - http://www.numdam.org/articles/10.1016/j.crma.2011.11.019/ DO - 10.1016/j.crma.2011.11.019 LA - en ID - CRMATH_2012__350_1-2_23_0 ER -
%0 Journal Article %A Benzekry, Sébastien %A Chapuisat, Guillemette %A Ciccolini, Joseph %A Erlinger, Alice %A Hubert, Florence %T A new mathematical model for optimizing the combination between antiangiogenic and cytotoxic drugs in oncology %J Comptes Rendus. Mathématique %D 2012 %P 23-28 %V 350 %N 1-2 %I Elsevier %U http://www.numdam.org/articles/10.1016/j.crma.2011.11.019/ %R 10.1016/j.crma.2011.11.019 %G en %F CRMATH_2012__350_1-2_23_0
Benzekry, Sébastien; Chapuisat, Guillemette; Ciccolini, Joseph; Erlinger, Alice; Hubert, Florence. A new mathematical model for optimizing the combination between antiangiogenic and cytotoxic drugs in oncology. Comptes Rendus. Mathématique, Tome 350 (2012) no. 1-2, pp. 23-28. doi : 10.1016/j.crma.2011.11.019. http://www.numdam.org/articles/10.1016/j.crma.2011.11.019/
[1] Mathematical and numerical analysis for a model of growing metastatic tumors, Math. Biosci., Volume 218 (2009), pp. 1-14
[2] Optimisation de la posologie et des modalités dʼadministration des agents cytotoxiques à lʼaide dʼun modèle mathématique, Bull. Cancer, Volume 90 (2003), pp. 167-175
[3] Modélisation du rique dʼévolution métastatique chez les patients supposés avoir une maladie localisée, Oncologie, Volume 13 (2011), pp. 528-533
[4] Mathematical and numerical analysis of a model for antiangiogenic therapy in metastatic cancers, M2AN, Volume 46 (2012), pp. 207-237
[5] S. Benzekry, N. André, A. Benabdallah, J. Ciccolini, C. Faivre, F. Hubert, D. Barbolosi, Modelling the impact of anticancer agents on metastatic spreading, MMNP (2011), in press.
[6] A population pharmacokinetic model for docetaxel (Taxotere): model building and validation, J. Pharmacokinet. Biopharm., Volume 24 (1996), pp. 153-172
[7] Treatment of metastatic colorectal cancer, Semin. Oncol., Volume 38 (2011), pp. 552-560
[8] Randomized comparison of etoposide pharmacokinetics after oral etoposide phosphate and oral etoposide, Br. J. Cancer, Volume 75 (1997), pp. 1660-1666
[9] Tumor angiogenesis: therapeutic implications, New England J. Med., Volume 285 (1971), pp. 1182-1186
[10] On the nature of the function expressive of the law of human mortality and on a new mode of determining the value of life contingencies, Phil. Trans. Roy. Soc. London, Volume 115 (1825), pp. 513-583
[11] Tumor development under angiogenic signaling: A dynamical theory of tumor growth, treatment response, and postvascular dormancy, Cancer Res., Volume 75 (1999), pp. 4770-4775
[12] A dynamical model for the growth and size distribution of multiple metastatic tumors, J. Theor. Biol., Volume 203 (2000), pp. 177-186
[13] Molecular regulation of vessel maturation, Nature Med., Volume 9 (2003), pp. 685-693
[14] Sound footing or slippery slope? The value of secondary analyses of randomized trials, J. Clin. Oncol., Volume 25 (2007), pp. 3191-3193
Cité par Sources :
